Oxford Biomedica’s share price hits record peaks as it upgrades forecasts!

The Oxford Biomedica share price has roared to new all-time peaks as vaccine orders from AstraZeneca increase. Here are the key points.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investor appetite for UK shares remains stable in Tuesday business, following last week’s heavy falls. Though fears over runaway inflation — allied with lingering concerns over the Covid-19 crisis — has stymied hopes of significant dip-buying interest. That said, the Oxford Biomedica (LSE: OXB) share price is picking up fresh momentum today.

At £11.14 per share, Oxford Biomedica was up 11% during Tuesday’s session. The FTSE 250 healthcare giant touched record highs around £11.28 earlier today, after announcing upgrades to its full-year earnings estimates.

Guidance gets a shot in the arm!

Oxford Biomedica — which manufactures the AstraZeneca coronavirus vaccine — has released a series of strong updates in recent months. And on Tuesday, it advised that the FTSE 100 firm has bumped up orders of the pandemic battler.

It said the “successful manufacture of large-scale batches” of Covid-19 vaccines meant AstraZeneca has “committed to an increase in the number of batches” in the second half of 2021. This follows on from the 18-month supply agreement both parties had signed back in September.

As a consequence, Oxford Biomedica said it was raising its revenues guidance from the AstraZeneca deal. It now predicts sales “in excess of £100m” from the Footsie firm, double its previous guidance of above £50m. It also added it expects “significant growth” in group operating earnings before interest, tax, depreciation and amortisation (EBITDA).

Arrowings ascending on a chalkboard

What Oxford Biomedica said

John Dawson, chief executive at Oxford Biomedica, said: “Everyone involved with production of the Covid-19 vaccine can be truly proud of their achievement in manufacturing batches of vaccine from our Oxbox manufacturing facility.

“We are delighted to be a key supplier of the vaccine and the group is proud to be part of this world-leading vaccination project that is saving many lives,” he added.

Finally, Oxford Biomedica reiterated its belief that it doesn’t expect its vaccine production agreement with AstraZeneca “to have any impact on the group’s current partnerships or ability to secure and support additional new partnerships in the cell and gene therapy field.”

Will profits forecasts leap?

As I say, this is the latest in a line of positive trading statements from Oxford Biomedica. Its full-year results of April showed revenues soared 37% year-on-year in 2020 to £87.7m. Consequently, the FTSE 250 firm saw pre-tax losses narrow significantly to £6.6m from £20.9m in 2019.

The business saw bioprocessing and commercial development revenues rocket 45% on an annual basis to £68.5m, it said. Trade here was helped by new contract wins with Astrazeneca, Beam Therapeutics and Bristol Myers Squibb. Meanwhile, the number of partner programmes grew from 13 in 2019 to 20 last year.

City analysts expect Oxford Biomedica to bounce back into profit in 2021. They had been predicting pre-tax profit of £6.9m this year, rising to £11m in 2022. Today’s news means these forecasts could be significantly upgraded.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Bristol Myers Squibb. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

Here’s how saving £5.40 a day could net me £1,971 yearly passive income for life

The price of a cup of coffee seems to have broken the £5 mark. Is it time to put that…

Read more »

Investing Articles

2 top FTSE 100 stocks surging to record highs (hint — not Rolls-Royce)!

Ben McPoland takes a closer look at a pair of high-performing FTSE 100 stocks that continue to enrich long-term shareholders.

Read more »

Investing Articles

A cheap FTSE 100 share to consider buying for the next 10 years!

This FTSE 100 share has pride of place in my portfolio. Here's why I think it could be a top…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 44% in 2 months! Is this FTSE 250 green energy pioneer priced too cheaply?

After a sharp tumble in recent months, this FTSE 250 company with a growing order book is almost 90% below…

Read more »

Investing Articles

Investing a £20k Stocks and Shares ISA in this high-yielder might give me a £2,000 annual income

Harvey Jones is now wondering whether to pour his entire Stocks and Shares ISA allowance into a single FTSE 100…

Read more »

Investing Articles

Saving £20k in an ISA? Here’s how I’m aiming to turn that into a stunning £2,035 monthly passive income

Harvey Jones is keen to build a high and rising passive income by investing in a balanced spread of top…

Read more »

Investing Articles

How I’ll aim to turn an empty ISA into a £100k nest egg buying cheap shares in 2025

Christopher Ruane explains how he thinks taking a long-term approach to buying cheap shares and holding them could help him…

Read more »

Investing Articles

I love my Legal & General shares even more after today’s exciting update

Harvey Jones had high hopes for Legal & General shares when he bought them last year. So far he's got…

Read more »